Thompson Siegel & Walmsley’s Impax Laboratories, Inc. IPXL Stock Holding History

Thompson Siegel & Walmsley’s Portfolio IPXL Stock Details IPXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-14,000	Closed	-$177K	–	926
2017 Q1	$177K	Buy	+14,000	New	+$169K	﹤0.01%	458
2015 Q4	–	Sell	-4,900	Closed	-$173K	–	740
2015 Q3	$173K	Buy	+4,900	New	+$221K	﹤0.01%	385
2014 Q3	–	Sell	-421,581	Closed	-$12.6M	–	712
2014 Q2	$12.6M	Buy	+421,581	New	+$11.4M	0.25%	173
2013 Q3	–	Sell	-23,900	Closed	-$477K	–	686
2013 Q2	$477K	Buy	+23,900	New	+$424K	0.01%	332

Other funds holding IPXL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Thompson Siegel & Walmsley's IPXL Position: Q2 2017 in Review

Thompson Siegel & Walmsley sold out of Impax Laboratories, Inc. (IPXL) in Q2 2017, closing a stake of 14,000 shares — an estimated $177K sold.

Thompson Siegel & Walmsley first reported a position in IPXL in Q2 2013 and held it in 4 quarters. The position peaked at $12.6M in Q2 2014. 172 funds tracked by Wall St. Rank hold IPXL as of Q2 2017.

Thompson Siegel & Walmsley reported no remaining Impax Laboratories, Inc. position as of Q2 2017 after selling out during the quarter.
Thompson Siegel & Walmsley sold 14,000 Impax Laboratories, Inc. shares in Q2 2017, an estimated $177K.
Thompson Siegel & Walmsley first reported a position in Impax Laboratories, Inc. in Q2 2013 and held it in 4 quarters.
Thompson Siegel & Walmsley's Impax Laboratories, Inc. position peaked at $12.6M in Q2 2014.
172 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q2 2017.

Based on Thompson Siegel & Walmsley's 13F filing for Q2 2017, filed 9 Aug 2017.